Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. is listed today as Minerva Neurosciences, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2016 | $1 M | Private placement after listing | Under $2 million | equity | SEC | |
| Mar 2015 | $31 M | Private placement after listing | $10 to $50 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Minerva Neurosciences, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2016).
SEC Form D · Mar 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2016
That is all the official record says: Minerva Neurosciences, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Minerva Neurosciences, Inc. are on record.
Investors#
No investor of Minerva Neurosciences, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Minerva Neurosciences, Inc. shares, as of Sep 30, 2026.
- Federated Hermes, Inc.$16 M9.37%
- Janus Henderson Group Ltd.$15 M8.99%
- Vivo Capital, LLC$14 M8.67%
- Balyasny Asset Management L.P.$14 M8.54%
- Logos Global Management LP$11 M6.60%
- BlackRock, Inc.$8 M4.92%
- Farallon Capital Management, L.L.C.$8 M4.75%
- Foresite Capital Management VI LLC$7 M3.98%
- Vanguard Capital Management LLC$7 M3.91%
- Ally Bridge Group (NY) LLC$6 M3.32%
- Spruce Street Capital LP$6 M3.32%
- Adage Capital Partners GP, L.L.C.$5 M2.85%
- Trails Edge Capital Partners, LP$5 M2.85%
- Millennium Management LLC$4 M2.54%
- Seven Fleet Capital Management LP$3 M2.01%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Fred Ahlholm | Executive officer | Mar 2016 |
| Geoff Race | Executive officer | Mar 2016 |
| Joseph Reilly | Executive officer | Mar 2016 |
| Mark Levine | Executive officer | Mar 2016 |
| Remy Luthringer | Executive officer | Mar 2016 |
| David Kupfer | Director | Mar 2016 |
| Fouzia Laghrissi-Thode | Director | Mar 2016 |
| Francesco De Rubertis | Director | Mar 2016 |
| Jan Van Heek | Director | Mar 2016 |
| Marc Beer | Director | Mar 2016 |
| Michele Ollier | Director | Mar 2016 |
| Nico Vandervelpen | Director | Mar 2016 |
| Remy Luthringer | Director | Mar 2016 |
About
Company in Waltham, United States.
Went public since 2014. Its SEC number is that of a company listed on a stock exchange.